DeepMed Research

The New York State Psychiatric Institute

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1895-01-01

Employees: 251

Market Cap: -

Website: http://www.nyspi.org

Clinical Trials

Ketamine in the Treatment of Suicidal Depression

Phase 4

Completed

Conditions: Suicidal Ideation
Major Depressive Disorder

Interventions: Drug: Midazolam
Drug: Ketamine

First Posted Date: 2012-10-04

Last Posted Date: 2020-03-11

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 82

Registration Number: NCT01700829

Locations: 🇺🇸
Columbia University/New York State Psychiatric Institute, New York, New York, United States

Quetiapine Pharmacotherapy for Cannabis Dependence

Phase 2

Completed

Conditions: Cannabis Dependence

Interventions: Drug: Placebo
Drug: Quetiapine

First Posted Date: 2012-10-02

Last Posted Date: 2019-03-05

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 130

Registration Number: NCT01697709

Locations: 🇺🇸
New York State Psychiatric Institute, New York, New York, United States

Novel Medication Strategies Targeting Brain Mechanisms in Pediatric OCD

Phase 2

Completed

Conditions: Obsessive Compulsive Disorder

Interventions: Other: Placebo
Drug: Minocycline

First Posted Date: 2012-09-27

Last Posted Date: 2019-11-13

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 31

Registration Number: NCT01695291

Locations: 🇺🇸
Weill Cornell Medical Center, New York, New York, United States
🇺🇸
New York State Psychiatric Institute, New York, New York, United States

Attaining and Maintaining Wellness in Obsessive-compulsive Disorder

Not Applicable

Completed

Conditions: Obsessive Compulsive Disorder

Interventions: Behavioral: Monthly Booster Sessions of EX/RP
Procedure: Visits with MD and independent evaluators

First Posted Date: 2012-09-17

Last Posted Date: 2019-03-13

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 137

Registration Number: NCT01686087

Locations: 🇺🇸
New York State Psychiatric Institute, New York, New York, United States
🇺🇸
University of Pennsylvania Center for the Treatment and Study of Anxiety, Philadelphia, Pennsylvania, United States

Combination Treatment Study for Memory Impairment and Depression

Phase 4

Completed

Conditions: Mild Cognitive Impairment
Depression

Interventions: Drug: Placebo
Drug: Donepezil
Drug: Citalopram
Drug: Venlafaxine

First Posted Date: 2012-08-06

Last Posted Date: 2017-10-17

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 86

Registration Number: NCT01658228

Locations: 🇺🇸
New York State Psychiatric Institute, New York, New York, United States
🇺🇸
Duke University, Durham, North Carolina, United States

Neurocircuitry of Autism- fMRI and Transcranial Magnetic Stimulation Studies

Not Applicable

Terminated

Conditions: Asperger Disorder
Autism Spectrum Disorder
Pervasive Developmental Disorder

Interventions: Device: TMS and functional MRI (Magstim)

First Posted Date: 2012-03-14

Last Posted Date: 2017-01-13

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 8

Registration Number: NCT01553240

Locations: 🇺🇸
New York state Psychiatric Institute, New York, New York, United States

Desvenlafaxine vs. Placebo Treatment of Chronic Depression

Phase 4

Completed

Conditions: Dysthymic Disorder
Dysthymia
Chronic Depressive Disorder

Interventions: Drug: Placebo
Drug: Desvenlafaxine

First Posted Date: 2012-02-22

Last Posted Date: 2017-09-11

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 59

Registration Number: NCT01537068

Locations: 🇺🇸
New York State Psychiatric Institute/3 Columbus Circle Midtown, New York, New York, United States
🇺🇸
Depression Evaluation Service (DES), New York State Psychiatric Institute, Columbia University Department of Psychiatry, New York, New York, United States

The Effect of Brief Potent Glutamatergic Modulation on Cocaine Dependence

Phase 1

Terminated

Conditions: Cocaine Dependence

Interventions: Drug: Ketamine
Drug: Midazolam

First Posted Date: 2012-02-20

Last Posted Date: 2019-05-01

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 55

Registration Number: NCT01535937

Locations: 🇺🇸
New York State Psychiatric Institute, New York, New York, United States

Pharmacologic and Clinical Testing of a D1 Agonist for Cognitive Enhancement in Neuropsychiatric Disorders

Early Phase 1

Completed

Conditions: Schizophrenia
Schizoaffective Disorder

Interventions: Drug: DAR-100A
Drug: Placebo

First Posted Date: 2012-01-27

Last Posted Date: 2015-03-04

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 68

Registration Number: NCT01519557

Locations: 🇺🇸
New York State Psychiatric Institute, New York, New York, United States

Imaging the Dopamine Systems in Bulimia Nervosa

Completed

Conditions: Eating Disorders

First Posted Date: 2011-12-16

Last Posted Date: 2014-08-15

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 33

Registration Number: NCT01493362

Locations: 🇺🇸
New York State Psychiatric Institute, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy